[The fibrate-activated PPARalpha/p16INK4A pathway inhibits vascular smooth muscle cell proliferation and vascular occlusion].
Gizard
Florence
F
Staels
Bart
B
D000818:Animals; D001161:Arteriosclerosis / Q000503:physiopathology / Q000517:prevention & control*; D002455:Cell Division; D002784:Cholesterol / Q000378:metabolism; D002995:Clofibric Acid / Q000494:pharmacology* / Q000627:therapeutic use; D023903:Coronary Restenosis / Q000517:prevention & control; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000502:physiology*; D005786:Gene Expression Regulation / Q000187:drug effects; D019942:Genes, p16; D006801:Humans; D006965:Hyperplasia; D051379:Mice; D018345:Mice, Knockout; D008955:Models, Cardiovascular; D009131:Muscle, Smooth, Vascular / Q000166:cytology*; D032389:Myocytes, Smooth Muscle / Q000166:cytology*; D047493:PPAR alpha / Q000502:physiology*; D015398:Signal Transduction / Q000187:drug effects; D017539:Tunica Intima / Q000187:drug effects / Q000473:pathology; D014657:Vasculitis / Q000150:complications
D019941:Cyclin-Dependent Kinase Inhibitor p16; D047493:PPAR alpha; D002995:Clofibric Acid; D002784:Cholesterol